

**OMTM, Volume 10**

## **Supplemental Information**

### **An Optimized Lentiviral Vector Efficiently**

### **Corrects the Human Sickle Cell Disease**

### **Phenotype**

**Leslie Weber, Valentina Poletti, Elisa Magrin, Chiara Antoniani, Samia Martin, Charles Bayard, Hanem Sadek, Tristan Felix, Vasco Meneghini, Michael N. Antoniou, Wassim El-Nemer, Fulvio Mavilio, Marina Cavazzana, Isabelle Andre-Schmutz, and Annarita Miccio**










Figure S1






**Figure S2. Erythroid differentiation of LV-transduced SCD HSPCs. (A)** Representative FACS histograms showing the frequency of cells expressing the early erythroid markers CD36 and CD71 and the late erythroid marker Glycophorin A (GYPA), and the proportion of DRAQ5- enucleated cells. RBCs derived from mock-,  $\beta$ -AS3 HS4- and  $\beta$ -AS3- transduced SCD HSPCs were analyzed at day 20 of erythroid differentiation. (B) Time-course FACS analysis of CD36, CD71 and GYPA expression and enucleation in samples derived from mock-,  $\beta$ -AS3 HS4- and  $\beta$ -AS3- transduced samples. Cells were analyzed at day 6 (D6), day 13 (D13) and day 20 (D20) of erythroid differentiation. Values shown are mean $\pm$ SEM of 3 experiments (n=2 donors). (C) Representative photomicrographs of RBCs obtained at day 20 of erythroid differentiation and stained with May-Grünwald Giemsa. Scale bars, 20  $\mu$ m.



**Figure S3. Human hematopoietic cell reconstitution in NSG mice transplanted with BM SCD cells.** Frequency of human erythroid (CD36), T (CD3) and B (CD19) lymphoid and myeloid (CD14 and CD15) cells in BM (**A**) and spleen (**B**) of mice transplanted with mock-,  $\beta$ -AS3 HS4- or  $\beta$ -AS3-transduced CD34<sup>+</sup> cells. (**C**) Percentage of CD3<sup>+</sup> T lymphoid cells in the thymus of transplanted mice. Mice transplanted with healthy donor peripheral blood G-CSF-mobilized (HD mPB) or cord blood (HD CB) HSPCs were used as controls. Each data point represents an individual mouse.



**Figure S4. Transgene expression in BFU-E derived from  $\beta$ -AS3 HS4- and  $\beta$ -AS3- transduced SCD BM HSPCs. (A)** Correlation between the levels of HBBAS3 mRNA expression. The slopes of the linear regression lines for samples transduced with  $\beta$ -AS3 HS4 (n=7) or  $\beta$ -AS3 (n=16) LVs were not significantly different ( $P=0.9672$ ; n=2 donors). Equations that define the best fit lines were  $y = 0.28x - 0.03$  ( $R^2=0.9339$  and  $P=0.0004$ ) for  $\beta$ -AS3 HS4 samples and  $y = 0.26x + 0.05$  ( $R^2=0.5913$  and  $P=0.0005$ ) for  $\beta$ -AS3 samples. **(B)** HbAS3 expression and the average VCN/cell in pools of BFU-E. The slopes of the linear regression lines for samples transduced with  $\beta$ -AS3 HS4 (n=5) or  $\beta$ -AS3 (n=13) LVs were not significantly different ( $P=0.8963$ ; n=2 donors). Equations that define the best fit lines were  $y = 7.51x + 13.35$  ( $R^2=0.1282$  and  $P=0.5540$ ) for  $\beta$ -AS3 HS4 samples and  $y = 9.16x + 9.32$  ( $R^2=0.8902$  and  $P<0.0001$ ) for  $\beta$ -AS3 samples.



**Figure S5. Human hematopoietic cell reconstitution in NSG mice transplanted with Plerixafor-mobilized SCD cells.** Percentage of erythroid, T and B lymphoid and myeloid markers in BM (A) and spleen (B) of mice transplanted with mock- or  $\beta$ -AS3-transduced HSPCs. (C) Frequency of T lymphoid cells in the thymus of transplanted mice. Each data point represents an individual mouse.